Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Dow Jones Top Company Headlines at 1 AM ET: Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk | BDO's ... Novo Nordisk and Pfizer are showing some desperation in their gloves-off ...

Coming up: earnings from AMD, Palantir, top pharmaceutical and tech firms; private-sector employment report; consumer sentiment.

All of this has weighed on stock performance, leaving the shares down almost 50% over the past three years. Considering this, ...

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Trump-Xi truce talks, Nvidia’s $5T milestone, Big Tech earnings, and Musk’s $1T showdown headline a packed week.

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker's $8.5 billion bid for the U.S. obesity ...